Table 2:

Multivariable analyses of the relationship between sociodemographic, health and vaccine-related variables on immunogenicity measures after first and second COVID-19 doses

Immunogenicity measure	Variable	Time point
		1 month after 1st dose			1 month after 2nd dose
		Estimate	95% CI	p	Estimate	95% CI	p
Log10 anti-RBD Abs	HIV	−0.2	−0.38 to −0.018	0.031	−0.0097	−0.18 to 0.16	0.91
	Age (per decade increment)	−0.094	−0.14 to −0.045	0.0002	−0.052	−0.093 to −0.011	0.013
	Male sex	−0.13	−0.31 to 0.044	0.14	0.00061	−0.1462 to 0.1474	0.99
	White Ethnicity	−0.12	−0.28 to 0.035	0.13	0.045	−0.08843 to 0.1789	0.51
	# Chronic conditions (per # increment)	−0.14	−0.24 to −0.041	0.0058	−0.11	−0.1955 to −0.03072	0.0073
	ChAdOx1 as first vaccine	−0.24	−0.51 to 0.035	0.087	-	-	-
	Dual ChAdOx1 regimen	-	-	-	−0.64	−0.99 to −0.29	0.0003
	Dose interval (per week increment)	-	-	-	0.023	0.000044 to 0.047	0.049
	Days since vaccine	0.023	−0.0010 to 0.047	0.06	−0.0033	−0.026 to 0.019	0.78
	COVID-19 convalescent	1.88	1.63 to 2.13	<0.0001	0.074	−0.14 to 0.29	0.50
ACE2 displacement (%)	HIV	−10.95	−20.35 to −1.56	0.023	0.64	−5.274 to 6.547	0.83
	Age (per decade increment)	−1.47	−3.14 to 0.41	0.13	−1.62	−2.72 to −0.52	0.0042
	Male sex	−6.94	−13.25 to −0.62	0.031	−2.17	−6.09 to 1.77	0.28
	White Ethnicity	−5.46	−10.95 to 0.031	0.051	1.181	−2.28 to 4.65	0.50
	# Chronic conditions (per # increment)	−0.85	−4.29 to 2.58	0.63	−2.71	−4.85 to −0.58	0.013
	ChAdOx1 as first vaccine	−18.77	−28.34 to −9.21	0.0001
	Dual ChAdOx1 regimen	-	-	-	−29.48	−38.50 to −20.47	<0.0001
	Dose interval (per week increment)	-	-	-	−0.24	−0.92 to 0.43	0.48
	Days since vaccine	0.52	−0.32 to 1.37	0.22	−0.12	−0.70 to 0.47	0.70
	EDTA as anticoagulant^	6.25	−3.74 to 16.23	0.22	1.17	−5.57 to 7.90	0.73
	COVID-19 convalescent	36.37	27.68 to 45.05	<0.0001	2.84	−2.75 to 8.44	0.32
log2 viral neutralization*	HIV	−0.28	−0.62 to 0.056	0.10	0.17	−0.51 to 0.84	0.63
	Age (per decade increment)	−0.047	−0.11 to 0.017	0.15	−0.18	−0.31 to −0.054	0.0055
	Male sex	−0.1	−0.33 to 0.12	0.38	−0.37	−0.82 to 0.077	0.10
	White Ethnicity	0.057	−0.14 to 0.25	0.57	−0.16	−0.56 to 0.24	0.42
	# Chronic conditions (per # increment)	0.046	−0.078 to 0.17	0.47	−0.29	−0.54 to −0.047	0.02
	ChAdOx1 as first vaccine	−0.14	−0.48 to 0.21	0.44	-	-	-
	Dual ChAdOx1 regimen	-	-	-	−1.37	−2.40 to −0.35	0.0088
	Dose interval (per week increment)	-	-	-	0.049	−0.028 to 0.13	0.21
	Days since vaccine	0.024	−0.061 to 0.55	0.12	−0.0092	−0.076 to 0.058	0.79
	EDTA as anticoagulant^	0.3	−0.061 to 0.66	0.1	0.83	0.061 to 1.60	0.035
	COVID-19 convalescent	3.9	3.60 to 4.22	<0.0001	1.07	0.43 to 1.70	0.0011

p-values that are statistically significant are in bold

^{^}analyses performed on plasma (i.e. ACE2 displacement and viral neutralization) also correct for the anticoagulant used, with ACD as the reference category.

Analyses of anti-RBD concentration do not correct for this variable because this assay was performed on serum.

^*for viral neutralization activity, reciprocal plasma dilutions were log₂ transformed prior to multivariable analysis, so estimates and 95% CI should be interpreted accordingly.